Cornerstone Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cornerstone Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$18.6M	Sell	213,219 -467,435	-69%	-$44.2M	2.93%	12
2016 Q2	$58.5M	Buy	680,654 +30,044	+5%	+$2.6M	3.09%	10
2016 Q1	$51.7M	Buy	650,610 +170,031	+35%	+$15.4M	2.26%	19
2015 Q4	$60.5M	Sell	480,579 -192,427	-29%	-$23.2M	2.47%	19
2015 Q3	$70.1M	Buy	673,006 +192,007	+40%	+$24.7M	2.97%	9
2015 Q2	$59.4M	Buy	+480,999	New	+$60.6M	1.95%	26

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cornerstone Capital Management's VRTX Position: Q3 2016 in Review

Cornerstone Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 69% in Q3 2016, selling an estimated $44.2M and leaving 213,219 shares worth $18.6M. The position accounts for 2.93% of the portfolio, ranked #12.

Cornerstone Capital Management first reported a position in VRTX in Q2 2015 and has held it in 6 quarters since. The position peaked at $70.1M in Q3 2015. 489 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

Cornerstone Capital Management held 213,219 shares of Vertex Pharmaceuticals worth $18.6M as of Q3 2016.
Cornerstone Capital Management sold 467,435 Vertex Pharmaceuticals shares in Q3 2016, an estimated $44.2M.
Vertex Pharmaceuticals made up 2.93% of Cornerstone Capital Management's portfolio in Q3 2016, its #12 holding.
Cornerstone Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 6 quarters since.
Cornerstone Capital Management's Vertex Pharmaceuticals position peaked at $70.1M in Q3 2015.
489 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Cornerstone Capital Management's 13F filing for Q3 2016, filed 3 Nov 2016.